Where DCP Midstream Stands With Analysts
Within the last quarter, DCP Midstream (NYSE:DCP) has observed the following analyst ratings:
RBC Capital Upgrades DCP Midstream to Outperform, Raises Price Target to $40
RBC Capital analyst Elvira Scotto upgrades DCP Midstream (NYSE:DCP) from Sector Perform to Outperform and raises the price target from $37 to $40.
Earnings Scheduled For May 4, 2022
Companies Reporting Before The Bell
• Seres Therapeutics (NASDAQ:MCRB) is estimated to report quarterly loss at $0.52 per share on revenue of $8.48 million.
Analyst Ratings For DCP Midstream
Analysts have provided the following ratings for DCP Midstream (NYSE:DCP) within the last quarter:
Earnings Scheduled For February 9, 2022
Companies Reporting Before The Bell
• Equinor (NYSE:EQNR) is projected to report quarterly earnings at $0.63 per share on revenue of $25.05 billion.
Barclays Maintains Overweight on DCP Midstream, Lowers Price Target to $35
Barclays analyst Christine Cho maintains DCP Midstream (NYSE:DCP) with a Overweight and lowers the price target from $38 to $35.
Citigroup Upgrades DCP Midstream to Buy, Raises Price Target to $34
Citigroup analyst Timm Schneider upgrades DCP Midstream (NYSE:DCP) from Neutral to Buy and raises the price target from $28 to $34.